Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.

Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Tiab M, Ramée JF, Chen JM, Kralovics R, Hermouet S.

Blood. 2011 Dec 8;118(24):6468-70. doi: 10.1182/blood-2011-08-372813. No abstract available.

2.

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.

Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, Saxena R.

Indian J Med Res. 2010 Oct;132:423-7.

3.

Genome-wide allele-specific analysis: insights into regulatory variation.

Pastinen T.

Nat Rev Genet. 2010 Aug;11(8):533-8. doi: 10.1038/nrg2815. Epub 2010 Jun 22. Review.

PMID:
20567245
4.

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP.

Blood. 2010 Apr 8;115(14):2882-90. doi: 10.1182/blood-2009-07-235119. Epub 2010 Jan 12.

5.

[Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].

Chae H, Lee JH, Lim J, Jung SW, Kim M, Kim Y, Han K, Cho BS, Cho SG, Lee JW, Min WS.

Korean J Lab Med. 2009 Jun;29(3):243-8. doi: 10.3343/kjlm.2009.29.3.243. Korean.

6.

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?

James C.

Hematology Am Soc Hematol Educ Program. 2008:69-75. doi: 10.1182/asheducation-2008.1.69. Review.

PMID:
19074061
7.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S.

Haematologica. 2009 Jan;94(1):38-45. doi: 10.3324/haematol.13486. Epub 2008 Nov 10.

8.

Genetic complexity of myeloproliferative neoplasms.

Kralovics R.

Leukemia. 2008 Oct;22(10):1841-8. doi: 10.1038/leu.2008.233. Epub 2008 Aug 28. Review.

PMID:
18754034
9.

Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.

Kondo T, Okuno N, Naruse H, Kishimoto M, Tasaka T, Tsujioka T, Matsuoka A, Sugihara T, Tohyama Y, Tohyama K.

Leuk Lymphoma. 2008 Sep;49(9):1784-91. doi: 10.1080/10428190802258972.

PMID:
18661406
10.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
11.

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C.

Ann Hematol. 2008 Jan;87(1):1-10. Epub 2007 Oct 16. Review.

12.
13.
14.

Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene.

Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, Kim JK.

Nucleic Acids Res. 2007;35(6):e40. Epub 2007 Feb 7.

15.
16.

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

Poodt J, Fijnheer R, Walsh IB, Hermans MH.

Hematol Oncol. 2006 Dec;24(4):227-33.

PMID:
17006961
17.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

18.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group.

Lancet. 2005 Dec 3;366(9501):1945-53.

PMID:
16325696
19.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC.

Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26.

20.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project.

Lancet. 2005 Mar 19-25;365(9464):1054-61. Erratum in: Lancet. 2005 Jul 9-15;366(9480):122.

PMID:
15781101

Supplemental Content

Support Center